DNAprint Genomics (DNAG)

[manysevens]

"And unless Biofrontera wants to just share these drugs with an american Penny Stock, then it's nothing more than just an investment." by STW

for your consideration ...

"Our relationship with Biofrontera will result in a new pharmaceutical pipeline for DNAPrint genomics," stated Mr. Gabriel, the Company's President and Chief Executive Officer. "Biofrontera already is in Phase II clinical trials with its BF-Derm1 lead product, an anti-itch compound for chronic Urticaria, known as chronic itching and welts brought on by exposure to cold or other allergens that cause a severe skin immune response. It also has a Phase II clinical trial compound for pre-cancerous skin lesions or actinic keratosis known as 5-aminolevulonic acid. Additionally, Biofrontera has advanced a novel prophylactic migraine treatment to pre-clinical development, as well as a series of other compounds at the pre-clinical stage."
http://biz.yahoo.com/iw/050714/090827.html